Background: We validated the DiaSorin Liaison Calcitonin_II-Gen, an improved method for calcitonin (CT) measurements, compared this method with the Cisbio_h-CT kit and established the reference range of CT in a normal adult population. Methods: We determined the precision, functional sensitivity, traceability to the 2nd IS 89/620, linearity and measurement uncertainty, accuracy profile and b-expectation limits. We evaluated the specificity, the susceptibility to human antianimal antibodies (HAMA), hook-effect and carry over. To establish a reference range, we selected 267 adults without renal insufficiency presenting with normal thyroid stimulating hormone (TSH), free thyroxin (T4) and calcium concentrations and without anti-thyroglobulin antibodies as our ''reference'' healthy population. We compared the method with Cisbio on 250 consecutive and 45 samples from a postpentagastrin stimulation test. Results: Precision (expressed as CV) was -10% for the measurement range, functional sensitivity: 5.3 ng/L and the method was found linear until to a 1/10 dilution. Uncertainty ranged from 25% to 7.2%, and the risk that one result falls out of the "20% acceptance limits was -5% between 2.9 and 1513 ng/L. The Bland and Altman plot showed no systematic bias between the two methods. The test is still prone to HAMA influence, does not present any hook-effect, although carry over was observed. Ninety-five percent of our adult reference population showed CT concentrations -7.4 ng/L, with an important gender difference: 95% of the men showed CT values -9.8 ng/L, whereas 95% of women were -4.0 ng/L. Conclusions: The Liaison Calcitonin_II-Gen is an analytically robust method. The important difference in gender observed in our population might lead to re-evaluation of the generally used ''10 ng/L'' cut-off in a multicentre prospective study.
Introduction
Calcitonin (CT) is a 32 amino acid calcium lowering peptide secreted by the C cells (parafollicular cells) of the thyroid. Serum CT is the most specific and sensitive marker of medullary thyroid carcinoma (MTC) for both the primary diagnosis and post-chirurgical follow-up (1, 2) . Although CT concentrations are higher in males than females, many laboratories use a cut-off value of 10 ng/L, instead of a population based reference interval. Indeed, different studies have shown that, in normal populations and in 90% of patients suffering from other nodular thyroid diseases, basal CT concentrations are below 10 ng/L (3-7). In clinical practice, patients with basal CT )10 ng/L should undergo a pentagastrin stimulation test to exclude the presence of MTC. Stimulated peak serum CT concentrations )100 ng/L are )90% specific for the diagnosis of C-cell disease, either Ccell hyperplasia or MTC (1, 6, 7) . However, it is important to point out that most of the reference studies have been established on the basis of data obtained with the Cisbio International immunoradiometric calcitonin assay (Gif-surYvette, France). Although, this kit is still recommended by some scientific societies, many laboratories have moved to more automated methods, either the Siemens Immulite 2000 family or the DiaSorin Liaison. We (8) and others (9) have already warned against the significant problems when the ''10 ng/L'' cut-off was used indiscriminately with the first version of the Liaison calcitonin kit.
Recently, DiaSorin (Stillwater, MN, USA) launched a new version of the calcitonin kit (Calcitonin_II-Gen) on the Liaison platform. The aim of this study was to evaluate the analytical performance of this new version of the Liaison calcitonin assay, and to compare the performance of this kit with the Cisbio International immunoradiometric method. We also determined the biological reference interval of this parameter in a well-described biologically ''normal'' adult population.
Materials and methods

Analytical methods
The Liaison Calcitonin_II-Gen assay is a one step sandwich chemiluminescent assay that uses a pair of affinity purified mouse antibodies. The kit is calibrated against the 2nd International Standard 89/620. The manufacturer claims that 1 mIU of the 2nd International Standard 89/620 corresponds to 3.6 pg of CT.
Statistical softwares
We used Medcalc (Mariakerke, Belgium) and e-noval (Arlenda, Liège, Belgium) software for statistical evaluation of the results.
Samples
We used serum samples only for CT determination. All samples were handled in according to our pre-analytical procedure: after collection of blood, samples were centrifuged at q48C at 3500 g, aliquoted and kept frozen at -208C until analysis.
Validation protocol
For validation, we evaluated the precision in accordance with a modified protocol based on CLSI EP-5A2: 12 serum pools were assayed in six replicates per day over five different days (360 determinations). The limit of quantification (or functional sensitivity) was assessed as the lowest value giving in inter-assay (on 10 different days) coefficient of variation of 20%. The linearity was evaluated in accordance with CLSI EP-6A. We studied the traceability to the 2nd International Standard 89/620. We evaluated measurement uncertainty, accuracy and the b-expectation limits: measurement uncertainty characterizes the dispersion of values around the true value and b-expectation tolerance limits with bs0.95 are the upper and lower values between which each future measurements of the same level has a 95% probability of being found (10, 11) . We consider that the method will provide accurate results if the 95% b-expectation tolerance interval at each concentration level is included totally in the acceptance limits that we decided to settle at "20% (12) .
We checked the specificity of the assay using 14 samples from patients treated by complete thyroidectomy and irradiation.
The presence of a hook effect was studied with samples spiked with very high amounts of the 2nd IS 89/620. Finally, we studied the susceptibility of the kit to present an interference with human anti-animal antibodies (HAMA) with three samples known to show interference with the previous version.
Comparison with the Cisbio_h-CT
We compared the results obtained with the two methods in 250 consecutive samples from our daily routine, and 45 samples obtained from patients following a pentagastrin stimulation test.
Establishment of the reference range
We evaluated the reference interval in a healthy adult population w122 women and 145 men; mean age: 56.4 years (L: 17; H: 87)x, selected on the basis of absence of anti-thyroglobulin antibodies and normal thyroid stimulating hormone (TSH) concentrations (0.3-3.6 mIU/L) and free thyroxin (T4) ( CT concentrations observed in men were significantly higher than those seen in women (median: 3.0 vs. 0.6 ng/L, respectively; p-0.0001). Ninety-five percent of the male population showed CT concentrations -9.8 ng/L (90% CI: 7.4-12.9 ng/L), whereas 95% of female were -4.0 ng/L (90% CI: 3.2-5.16 ng/L). Taken as a whole, 95% of the reference population showed CT concentrations below 7.4 ng/L and 97.5% were -11.3 ng/L. The distribution of CT concentrations in our reference population is shown on Figure 1 .
Analytical performance
Results of the precision evaluation are shown in Table 1 Article in press -uncorrected proof was found to be linear up to a 1/10 dilution. Measurement uncertainty and b-expectation tolerance limits observed in the 12 pools that were studied are presented in Table 2 . Measurement uncertainty was between 25.0% and 7.2%. The b-expectation tolerance intervals were computed at each concentration with a probability bs95%. This means that, on average, 95% of future results generated by this method will be included in the tolerance intervals. Indeed, tolerance interval methodology is predictive. The method will provide accurate results if the 95% b-expectation tolerance interval at each concentration is fully included in the acceptance limits that were established at "20%. Figure 2 illustrates this using an accuracy profile. As shown in this Figure, the method provided accurate results from 5.3 to 1513 ng/L. These two concentrations are the lower and upper limits of quantitation, respectively. Thus, they define the dosing range of the method. Indeed, it is guaranteed that all future results will be included within "20% with a probability of 95%.
In the 14 samples from patients treated by complete thyroidectomy and irradiation, 13 showed undetectable (-1 ng/L) concentrations of CT, one showed a value of 1.15 ng/L.
We did not observe any hook effect with samples containing up to 1 million ng/L. However, there was carry-over, with a blank sample showing a value of 8 ng/L after being measured following analysis of the sample with 1 million ng/L of CT.
We selected three samples that showed spurious elevated values with the first version of the kit (17, 43 and 91 ng/L) due to HAMA interference. Following treatment with the Scantibodies heterophile blocking tubes (HBT: Scantibodies, Santee, CA, USA), concentrations returned to -10 ng/L. Also, when measured with the Cisbio kit, these three samples showed values of, respectively, 9.3, 2.7 and 0.1 ng/L. In these three samples, the Liaison Calcitonin_II-Gen gave also spurious results (10.1, 71 and 113 ng/L), that were measured as -5 ng/L after HBT treatment.
Comparison with Cisbio_h-CT
We compared the two methods using 250 consecutive patients with the Bland and Altman plot ( Figure 3) . As can be seen in the Figure, there was no systematic bias between the two methods (mean differences0.1 ng/L), and the standard deviation of the differences was 2.0 ng/L. We did not find any significant difference with the Wilcoxon test wMedian (95% CI): Liaison: 1.62 ng/L (1.32-2.03) and Cisbio: 1.53 ng/L (1.31-2.0)x. In the 45 samples obtained after pen-ᮋ Article in press -uncorrected proof 
Discussion
We present the results of the analytical validation of the DiaSorin Liaison Calcitonin_II-Gen assay. Our results show that this method is sensitive and precise. We also established the measurement uncertainty and showed that between 5.3 and 1513 ng/L, 95% of results will be within "20% maximum allowable total error. The results of the Liaison Calcitonin_II-Gen are in accordance with those obtained with the Cisbio_h-CT, which was the method used to develop the interpretative guidelines. The Calcitonin_II-Gen is calibrated against the 2nd IS 89/620. However, this new version of the kit is still sensitive to HAMA interference: samples showing values )10 ng/L should be treated to remove this interference.
In 2007, Bieglmayer et al. checked the specificity of the first version of the Liaison CT kit by using 15 samples from patients treated with complete thyroidectomy. They found detectable CT concentrations in nine. They concluded that this former assay was prone to non-specific effects causing incorrect CT detection in patients free of thyroid tissue (14) . We found here that 1 of 14 thyroidectomized patients showed detectable CT concentrations. This patient had recently been diagnosed as suffering from a seronegative form of polyarthritis. Our tests for RF or HAMA interference are inconclusive at such low CT concentrations, and thus we could not conclude if we observed analytical interference or a lack of specificity of the assay for this particular patient. However, we can conclude that the specificity of the new Liaison CT assay is greatly improved compared to the former.
According to D'Herbomez et al. (15), we defined our ''normal'' population as a population of adult men and women showing normal concentrations of TSH, free T4, and calcium. These patients did not show anti-thyroglobulin antibodies and did not suffer from renal insufficiency. Unfortunately, we had no information on the smoking status of these patients. As expected, the results observed were much lower in women compared to those observed in men. Even if 95% of our ''normal'' patients showed CT concentrations -7.4 ng/L -and thus below 10 ng/L -the 95th percentile for women population was very low, at 4.0 ng/L. Thus, the Liaison Calcitonin_II-Gen still lacks sensitivity, as more than 95% of the values observed in women will be reported as ''-5.3 ng/L''.
Machens et al. recently claimed gender specific CT thresholds for screening for occult MCT (16) . Contrary, Rink et al. advocated that a cut-off of 15 ng/L (as established with the IBL Calcitonin IRMA or Medipan Calcitonin-IRMA magnum) instead of the ''traditional'' 10 ng/L for basal CT was able to detect all MTC and reduced the number of false positive cases (17) . The debate on the use of a ''clinical'' cut-off value or cut-off values derived from apparently healthy people for MTC screening is still ongoing. Our study was purely analytical and neither designed nor powered to establish CT ''clinical'' cut-offs. However, in the light of our results, it might be interesting to re-evaluate the ''10 ng/L'' cut-off in a large multicentre prospective study, across a wide spectrum of validated CT assays. This point is particularly important as the transposition of clinical cut-offs established from one method to other methods have shown important limitations (see PTH cut-offs in the former KDOQI Guidelines or GH cut-offs in the diagnosis of growth-hormone deficiency).
Finally, whatever the cut-off value(s) that is used, one should not forget that basal serum CT concentrations should always be interpreted in accordance with the clinical context. Indeed, it presents a low predictive positive value of 15.4%, reflecting many false positive results, potentially leading to Article in press -uncorrected proof unnecessary surgery (18) . Nevertheless, CT measurements are still recommended by the European Thyroid Cancer Taskforce for the initial diagnostic evaluation of thyroid nodules (19) . Also, a recent American study concluded that routine CT screening for MTC in patients with thyroid nodules could be as efficient as widely accepted screening programs, like measurement of TSH, colonoscopy and mammography (20) .
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